Natco Pharma Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ujvs5kpeban1tzc8i8293k3h.pdf

Key Takeaways


Quarterly Performance & Profit Bridge

Rajeev Nannapaneni: "The real value is always doing the niches and the hard to do generics where they're limited amount of competition. That's where the real money is."

Agro Business Turnaround


US Strategy & Pipeline

Rajeev Nannapaneni: "We have enough in our pipeline, my friend. I think I named quite a few ideas. But I think if you pull up another five, six ideas, I think you'll see some consistency going into the next decade."

Capital Allocation & M&A

Rajeev Nannapaneni: "I won't lever to answer your question. The reason is I'm conservative. I think we take a lot of long-term debts. I never -- a big fan of borrowing a large amount of money to do an acquisition. I think we'll do it with the cash flow we have and I think we have a strong enough balance sheet and if the right opportunity comes, I'll never say never."

Domestic Business & Subsidiaries


Guidance & Commitments

CommitmentSpecificsTimeline
Q2 performanceQuarter similar to Q1 in EBITDA margins and salesQ2 FY24
Full-year profit after taxINR1,000 crores to INR1,200 crores, depending on market conditionsFY24
Agro full-year revenueINR150 crores to INR200 croresFY24
Agro 3-4 year revenueINR400 crores to INR500 croresFY27-28
Agro EBITDA marginClose to base pharma business marginsSteady-state
Domestic growth rate10% to 15% over last year's baseFY24
Agro product launchesAt least 5 to 10 unique differential productsNext financial year
Quarterly phasingQ3 will taper off; Q4 will pick upFY24
CTPR market share target10% to 15%No date (season-dependent)

Key Metrics

MetricQ1 FY24
Consolidated total revenue₹1,160 cr, +26% YoY from ₹918.9 cr
Net profit₹420.3 cr, +31.2% YoY from ₹320.4 cr
Operating margin45.6%
Provision for patent litigation₹51 cr, booked during the quarter for pending infringement cases
One-time employee incentive₹17 cr, special incentive linked to company success
Domestic business growth guidance10% to 15% over the base of last year
Profit after tax guidance (full year FY24)₹1,000 cr to ₹1,200 cr, management estimate
Agro division revenue₹45 cr, up from ₹1 cr in prior comparable periods
Agro division full-year revenue target₹150 cr to ₹200 cr
Agro division 3–4 year revenue target₹400 cr to ₹500 cr
Subsidiaries revenue~₹130 cr, driven by Canada and Brazil
Cash and cash equivalents (as of July 31)₹1,386 cr, with debt of ₹104 cr mostly for bill discounting
Buyback spend₹210 cr plus tax, total about ₹250 cr
Dividend declared₹125 cr
Capacity utilization60% to 65%